铅-212标记PSMA放射性配体治疗联合利鲁唑作为放射增敏剂首次人体应用
本文报道首例经多线系统治疗和放射性配体治疗进展的转移性去势抵抗性前列腺癌(mCRPC)患者,接受[212Pb]Pb-PSMA放射性配体治疗联合mGluR抑制剂利鲁唑。该联合方案耐受良好,获得部分缓解、PSA下降及症状稳定,为首例[212Pb]Pb-PSMA联合mGluR抑制的人体应用。
要点
- 首例[212Pb]Pb-PSMA放射性配体治疗联合利鲁唑用于mCRPC患者。
- 联合方案耐受良好,出现部分缓解、PSA下降和症状稳定。
- 该策略靶向前列腺癌谷氨酰胺成瘾并利用放射增敏。
核心结论
- [212Pb]Pb-PSMA放射性配体治疗联合mGluR抑制剂利鲁唑在mCRPC首例人体应用中耐受良好并获临床获益。
研究设计与样本
- 首例人体病例报告:一例经多线系统治疗和放射性配体治疗进展的mCRPC患者接受联合治疗。
主要发现
- 联合治疗耐受良好,导致疾病部分缓解、PSA值下降和症状稳定。
临床怎么用
- 该联合策略可能为晚期、治疗难治、进展的mCRPC患者提供有前景的治疗选择,并有分子影像和临床获益支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present the first metastatic castration-resistant prostate cancer (mCRPC) patient, heavily pretreated with multiple systemic and radioligand therapies, who received [212Pb]Pb-PSMA radioligand therapy (PRLT) combined with the metabotropic glutamate receptor (mGluR)-inhibitor Riluzole due to disease progression. This novel combination, aimed at targeting glutamine addiction in prostate cancer and exploiting radio-sensitization, was well tolerated leading to partial remission of the disease, decrease in PSA values, and stability of symptoms. This represents the first-in-human clinical application of [212Pb]Pb-PSMA PRLT combined with mGluR inhibition in mCRPC, representing a promising therapeutic strategy for advanced, treatment-refractory, progressing patients, supported by molecular imaging and clinical benefit.
引用
- Perrone E, Greifenstein L, Ghai K, et al. First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer. Clin Nucl Med. 2025. PMID: 41921940. doi:10.1097/RLU.0000000000006222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。